iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody,…
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat’s Gut Microbiome Effects from Other Anti-CDI Antibiotics
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ)…
Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…